Novartis has been studying branaplam in SMA, but last year hinted that it would pivot to new neurological diseases after its head of research Jay Bradner said he did not see a "big opportunity" in its original disease indication.
The drug remains under study for SMA, but now Novartis said it wants to see if trials in humans can duplicate preclinical models in which branaplam was shown to reduce levels of a mutant protein that plays a role in Huntington's disease, for which there are no approved disease modifying therapies that delay disease onset or slow progression.
"Novartis intends to start a development program for branaplam to determine if it has the potential to be a transformative treatment for people living with this devastating condition," the company said in a statement.
Roche beat Novartis's branaplam to the market with an oral SMA therapy, Evrysdi, which was approved earlier this year.
By Reuters Staff
© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)
Posted on
Previous Article
« Probiotics promising for Parkinson’s constipation Next Article
Rates of bone density testing in men initiating ADT low but rising »
« Probiotics promising for Parkinson’s constipation Next Article
Rates of bone density testing in men initiating ADT low but rising »
Related Articles
December 24, 2021
MRI shows promise in diagnosing chronic traumatic encephalopathy
August 18, 2021
‘Mozart effect’ in epilepsy: why Mozart tops Haydn
November 25, 2020
Outcomes in patients on alemtuzumab with thyroid adverse events
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy